I think much of the volatility we are seeing now is due to...

I think much of the volatility we are seeing now is due to current shareholders who find themselves with a shareholding in a small biotech whose dollar value in their portfolios now equals the rest of their portfolio holdings combined. It makes sense to many to "take profits" in order to keep a diversified portfolio.

When dosing actually occurs I expect a "sell the news" effect. Providing there is not a calamitous adverse immunologic reaction in the first patient (possible I guess??), then we may then see a strong share price appreciation in the week or so following dosing as safety risk decreases.